Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108433 · ClinicalTrials.gov registry record · Phase 3
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
NCT00108433 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 61 participants.
The verdict
NCT00108433, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
Interventions
- DRUG Vancomycin (IV)
- DRUG Cefazolin IV
- DRUG Linezolid IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108433
The ClinicalTrials.gov registry entry for NCT00108433 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vancomycin (IV) is the first listed.
NCT00108433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108433 about?
NCT00108433 is a clinical study titled "Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections". This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
What is the current status of trial NCT00108433?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2005-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00108433?
The interventions under investigation include: Vancomycin (IV) (DRUG), Cefazolin IV (DRUG), Linezolid IV (DRUG).
Who is sponsoring clinical trial NCT00108433?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.